Therapeutic Vaccines Market: By Product Type (Conjugate Vaccines, Live Attenuated Vaccines, Inactivated and Subunit Vaccines, Toxoid Vaccines, Recombinant Vaccines), By Application (Infectious Diseases, Oncology, Addiction, Autoimmune Diseases, Neurological Diseases, Others), By Technology (Autologous Vaccines, Allogeneic Vaccines), By Valency (Monovalent vaccines, Multivalent vaccines), By End-user (Hospitals, Clinics, Others) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Therapeutic Vaccines Market size was valued at USD 28.4 billion in 2023 and is poised to grow at a significant CAGR of 18.03% from 2024-2030. Therapeutic vaccines are biological combinations that develop immunity against a diseased tissue or cell. Therapeutic vaccines are administered to the patient to induce a defense mechanism against a particular disease. These are developed to treat various cancer diseases, HIV, Alzheimers disease etc. Prophylactic vaccines differ from therapeutic vaccines and are used for the prevention and control of diseases, while prophylactic vaccines are only used for the prevention of diseases. Therapeutic vaccines are specially manufactured for HIV-positive individuals with a healthy immune system, to increase the ability to fight against microorganisms. Therapeutic vaccines are currently developed for chronic viral infections, such as human immunodeficiency virus (HIV), human papillomavirus (HPV), herpes simplex virus (HSV), cancer, hepatitis B virus, and hepatitis C virus etc. as an alternative to antiviral treatment.

The global therapeutic vaccines market is in the nascent stage where many players are actively involved in the development of therapeutic vaccines. Few companies have adopted some key business strategies, such as product innovation, and new product launching to ensure their dominance in the global therapeutic vaccines market. The global therapeutic vaccines market is positively affected by the significant rise in prevalence of chronic diseases such as cancer, and HIV etc. Few companies have taken an active lead in research and development of therapeutic vaccines. For instance, in April 2010, Dendreon Corporation, launched FDA approved immunotherapy drug Provenge, for the treatment of prostate cancer. According to U.S. Department of Health and Human Services, there are some vaccines in the clinical trial stage, such as Lucanix (Belagenpumatucel-L), gp100 melanoma vaccine, for Non-small cell lung cancer. Similarly, Merck & Co., Inc. and GSK Plc. are expected to launch vaccines such as GSK1572932A, and GV1001 having entered phase 3 trials.

Global Therapeutic Vaccines Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

18.03%

Largest Market

North America

Fastest Growing Market

North-America
Therapeutic Vaccines Market Dynamics

The global market is expected to grow at a significant CAGR due to increase in the prevalence of chronic diseases such as cancer, and HIV etc. According to World Health Organisation, an escalation of the diseases such as cancer (approximately 8.8 Mn people died in 2015) and HIV expected to drive the growth of global market over the forecasting period. The advanced and active R&D activities for therapeutic vaccines by pharmaceutical companies for various types of cancers are in pipeline which is expected to create potential opportunity in the global market in future. Apart from this, rising number of mergers and acquisitions, and an increase in funding from government for development of therapeutic vaccines might fuel the growth of global therapeutic vaccines market over the forecasting period. However, inefficient research and development and non-existent reimbursement policies for vaccines are the primary factors which are expected to hinder the growth of global market. Similarly, stringent regulatory implications, higher cost of vaccines, lesser accessibility to the vaccines, availability of alternative treatments for the diseases, and some adverse effects associated with the vaccines might hamper the growth of global therapeutic vaccines market over the forecast period.

Global Therapeutic Vaccines Market Segmentation

By Product Type
  • Conjugate
  • Live Attenuated Vaccines
  • Inactivated and Subunit Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
By Application
  • Infectious Diseases
  • Oncology
  • Addiction
  • Autoimmune Diseases
  • Neurological Diseases
  • Others
By Technology
  • Autologous Vaccines
  • Allogeneic Vaccines
By End User
  • Hospitals
  • Clinics
  • Others
By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

The Therapeutic vaccines market size was valued at USD 28.4 billion in 2022.

The Therapeutic vaccines market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

The Therapeutic vaccines market key players are Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi (France), Dendreon (U.S.), Agenus Inc. (U.S.), Valeant (Canada), Bavarian Nordic (Denmark), Pfizer, Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.)

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Therapeutic Vaccines Market Introduction 
2.1.Global Therapeutic Vaccines Market  - Taxonomy
2.2.Global Therapeutic Vaccines Market  - Definitions
2.2.1.Product Type
2.2.2.Application
2.2.3.Technology
2.2.4.End User
2.2.5.Region
3.Global Therapeutic Vaccines Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Therapeutic Vaccines Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Therapeutic Vaccines Market  By Product Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Conjugate
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Live Attenuated Vaccines
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Inactivated and Subunit Vaccines
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Toxoid Vaccines
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Recombinant Vaccines
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6.Global Therapeutic Vaccines Market  By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Infectious Diseases
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Oncology
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Addiction
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Autoimmune Diseases
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Neurological Diseases
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Others
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
7.Global Therapeutic Vaccines Market  By Technology, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Autologous Vaccines
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Allogeneic Vaccines
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
8.Global Therapeutic Vaccines Market  By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Hospitals
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Clinics
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Others
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Therapeutic Vaccines Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Therapeutic Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Conjugate
10.1.2.Live Attenuated Vaccines
10.1.3.Inactivated and Subunit Vaccines
10.1.4.Toxoid Vaccines
10.1.5.Recombinant Vaccines
10.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Infectious Diseases
10.2.2.Oncology
10.2.3.Addiction
10.2.4.Autoimmune Diseases
10.2.5.Neurological Diseases
10.2.6.Others
10.3.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Autologous Vaccines
10.3.2.Allogeneic Vaccines
10.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospitals
10.4.2.Clinics
10.4.3.Others
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Therapeutic Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Conjugate
11.1.2.Live Attenuated Vaccines
11.1.3.Inactivated and Subunit Vaccines
11.1.4.Toxoid Vaccines
11.1.5.Recombinant Vaccines
11.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Infectious Diseases
11.2.2.Oncology
11.2.3.Addiction
11.2.4.Autoimmune Diseases
11.2.5.Neurological Diseases
11.2.6.Others
11.3.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Autologous Vaccines
11.3.2.Allogeneic Vaccines
11.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospitals
11.4.2.Clinics
11.4.3.Others
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
11.5.6.Rest of EU
12.Asia Pacific (APAC) Therapeutic Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Conjugate
12.1.2.Live Attenuated Vaccines
12.1.3.Inactivated and Subunit Vaccines
12.1.4.Toxoid Vaccines
12.1.5.Recombinant Vaccines
12.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Infectious Diseases
12.2.2.Oncology
12.2.3.Addiction
12.2.4.Autoimmune Diseases
12.2.5.Neurological Diseases
12.2.6.Others
12.3.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Autologous Vaccines
12.3.2.Allogeneic Vaccines
12.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospitals
12.4.2.Clinics
12.4.3.Others
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Therapeutic Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Conjugate
13.1.2.Live Attenuated Vaccines
13.1.3.Inactivated and Subunit Vaccines
13.1.4.Toxoid Vaccines
13.1.5.Recombinant Vaccines
13.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Infectious Diseases
13.2.2.Oncology
13.2.3.Addiction
13.2.4.Autoimmune Diseases
13.2.5.Neurological Diseases
13.2.6.Others
13.3.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Autologous Vaccines
13.3.2.Allogeneic Vaccines
13.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospitals
13.4.2.Clinics
13.4.3.Others
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Therapeutic Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Conjugate
14.1.2.Live Attenuated Vaccines
14.1.3.Inactivated and Subunit Vaccines
14.1.4.Toxoid Vaccines
14.1.5.Recombinant Vaccines
14.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Infectious Diseases
14.2.2.Oncology
14.2.3.Addiction
14.2.4.Autoimmune Diseases
14.2.5.Neurological Diseases
14.2.6.Others
14.3.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Autologous Vaccines
14.3.2.Allogeneic Vaccines
14.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospitals
14.4.2.Clinics
14.4.3.Others
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Merck & Co., Inc. (U.S)
15.2.2.GlaxoSmithKline plc (U.K)
15.2.3.Novartis AG (Switzerland)
15.2.4.Sanofi (France)
15.2.5.Dendreon (U.S)
15.2.6.Agenus Inc. (U.S)
15.2.7.Valeant (Canada)
15.2.8.Bavarian Nordic (Denmark)
15.2.9.Pfizer, Inc. (U.S)
15.2.10.Inovio Pharmaceuticals, Inc. (U.S)
16. Research Methodology 
17. Appendix and Abbreviations 
  • Merck & Co., Inc. (U.S)
  • GlaxoSmithKline plc (U.K)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Dendreon (U.S)
  • Agenus Inc. (U.S)
  • Valeant (Canada)
  • Bavarian Nordic (Denmark)
  • Pfizer, Inc. (U.S)
  • Inovio Pharmaceuticals, Inc. (U.S)

Adjacent Markets